norfloxacin has been researched along with Leukemia, Lymphoid in 2 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Leukemia, Lymphoid: Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the effect of norfloxacin, 400 mg given orally every 12 hours, on the prevention of bacterial infections in 68 adult patients who had acute leukemia throughout prolonged courses of granulocytopenia (median, 32 days)." | 9.06 | Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1987) |
| "We evaluated the effect of norfloxacin, 400 mg given orally every 12 hours, on the prevention of bacterial infections in 68 adult patients who had acute leukemia throughout prolonged courses of granulocytopenia (median, 32 days)." | 5.06 | Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1987) |
| " We have previously demonstrated that the ability to suppress bacterial colonization of this site with oral norfloxacin prophylaxis (400 mg every 12 h) affects the incidence and distribution of aerobic gram-negative bacterial infections and the overall management of infectious complications in this patient population." | 3.67 | Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient. ( Dick, JD; Karp, JE; Merz, WG, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karp, JE | 2 |
| Dick, JD | 1 |
| Merz, WG | 2 |
| Hendricksen, C | 1 |
| Laughon, B | 1 |
| Redden, T | 1 |
| Bamberger, BJ | 1 |
| Bartlett, JG | 1 |
| Saral, R | 1 |
| Burke, PJ | 1 |
1 trial available for norfloxacin and Leukemia, Lymphoid
| Article | Year |
|---|---|
Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Agents | 1987 |
1 other study available for norfloxacin and Leukemia, Lymphoid
| Article | Year |
|---|---|
Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient.
Topics: Administration, Oral; Agranulocytosis; Bacterial Infections; Digestive System; Gastrointestinal Dise | 1988 |